Akari Therapeutics (FRA:CLA) Deferred Tax : €0.00 Mil (TTM As of Jun. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Akari Therapeutics Deferred Tax?

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Akari Therapeutics's change in deferred tax for the three months ended in Jun. 2024 was €0.00 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Jun. 2024 was €0.00 Mil.

Akari Therapeutics Deferred Tax Historical Data

The historical data trend for Akari Therapeutics's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akari Therapeutics Deferred Tax Chart

Akari Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Deferred Tax

Get a 7-Day Free Trial

Akari Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Mar23	Jun23	Dec23	Mar24	Jun24
Deferred Tax	Get a 7-Day Free Trial															-	-	-	-	-

Akari Therapeutics Deferred Tax Calculation

Deferred Tax for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Akari Therapeutics Deferred Tax Related Terms

Thank you for viewing the detailed overview of Akari Therapeutics's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.

Akari Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akari Therapeutics PLC (FRA:CLA) » Definitions » Deferred Tax

Comparable Companies

Traded in Other Exchanges

AKTX:USA

Address

75/76 Wimpole Street, London, GBR, W1G 9RT

Website

https://www.akaritx.com

Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system for the treatment of rare and orphan diseases. Its main product candidate includes Coversin, Coversin long acting and Coversin dual action. It operates mainly in United States and United Kingdom.